Andrew Davies MRCP, PhD, University of Southampton, Southampton, UK, describes changes in the treatment of diffuse large B-cell lymphoma (DLBCL) in the face of COVID-19, including modifying delivery of therapies as well as the implementation of phone/video consulations. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).